What do systematic reviews say?

Bevacizumab plus chemotherapy vs chemotherapy alone

Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 0.77 [0.62, 0.95]
  1 study · 452 participants
  Low

Pazopanib plus lapatinib vs lapatinib

Pazopanib plus lapatinib may leads to higher overall survival compared with lapatinib (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 2.71 [1.16, 6.31]
  1 study · 117 participants
  Low

Pazopanib vs lapatinib

Pazopanib showed no clear difference in overall survival compared with lapatinib (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 0.96 [0.67, 1.38]
  1 study · 152 participants
  Low

Cediranib plus chemotherapy vs placebo plus chemotherapy

Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 0.94 [0.53, 1.65]
  1 study · 69 participants
  Low

Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery

It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes overall survival compared with stereotactic radiosurgery (very low certainty).

• Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis 2018 · Cochrane Headline outcomes only
  HR 0.92 [0.48, 1.77]
  1 study · 64 participants
  Very low

Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery plus WBRT

Surgery plus whole brain radiotherapy (WBRT) showed no clear difference in overall survival compared with stereotactic radiosurgery plus WBRT (low certainty).

• Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis 2018 · Cochrane Headline outcomes only
  HR 0.53 [0.2, 1.42]
  1 study · 21 participants
  Low

Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT

Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) showed no clear difference in overall survival compared with WBRT (moderate certainty).

• Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases 2017 · Cochrane Headline outcomes only
  HR 0.82 [0.65, 1.02]
  2 studies · 358 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in overall survival (moderate certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  HR 1.07 [0.81, 1.43]
  2 studies · 1851 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in overall Survival (median (low certainty).

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  HR 1.11 [0.83, 1.48]
  5 studies · 663 participants
  Low

Lifestyle interventions vs placebo or usual care

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Low

Lifestyle interventions vs placebo or usual care

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  RR 0.23 [0.01, 4.55]
  1 study · 37 participants
  Very low

Oestrogen therapy alone vs placebo

The review found no eligible studies for this question.

• Hormone replacement therapy for women previously treated for endometrial cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  HR 1.32 [0.98, 1.78]
  1 study · 231 participants
  Low

mTOR inhibitors vs chemotherapy/hormone therapy

mTOR inhibitors showed no clear difference in overall survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  HR 1.06 [0.7, 1.61]
  1 study · 130 participants
  Low

Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT

WBRT and radiosurgery showed no clear difference in overall survivalNo. of participants: 358(2 RCTs) compared with WBRT (moderate certainty).

• Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
  HR 0.61 [0.27, 1.39]
  Studies not reported
  Moderate

Radiosurgery alone vs WBRT and radiosurgery

Radiosurgery alone showed no clear difference in overall survivalNo. of participants: 403(3 RCTs) compared with WBRT and radiosurgery (moderate certainty).

• Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
  HR 1 [0.8, 1.25]
  Studies not reported
  Moderate

WBRT with radiosensitisers (radiosen) vs WBRT

WBRT with radiosensitisers (radiosen) showed no clear difference in overall survivalNo. of participants: 2631(8 RCTs) compared with WBRT alone (moderate certainty).

• Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
  HR 1.05 [0.99, 1.12]
  Studies not reported
  Moderate

Laparoscopy vs laparotomy

Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).

• Laparoscopy versus laparotomy for the management of early stage endometrial cancer 2018 · Cochrane Headline outcomes only
  HR 1.04 [0.86, 1.25]
  6 studies · 3993 participants
  Moderate

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 0.9 [0.51, 1.6]
  1 study · 52 participants
  Low